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Myeloproliferative neoplasms (MPNs) are associated with significant alterations in the bone marrow microenvironment
that include decreased expression of key niche factors and myelofibrosis. Here, we explored the contribution of TGF-β to
these alterations by abrogating TGF-β signaling in bone marrow mesenchymal stromal cells. Loss of TGF-β signaling in
Osx-Cre–targeted MSCs prevented the development of myelofibrosis in both MPLW515L and Jak2V617F models of MPNs. In
contrast, despite the absence of myelofibrosis, loss of TGF-β signaling in mesenchymal stromal cells did not rescue the
defective hematopoietic niche induced by MPLW515L, as evidenced by decreased bone marrow cellularity, hematopoietic stem/
progenitor cell number, and Cxcl12 and Kitlg expression, and the presence of splenic extramedullary hematopoiesis. Induction
of myelofibrosis by MPLW515L was intact in Osx-Cre Smad4fl/fl recipients, demonstrating that SMAD4-independent TGF-β
signaling mediates the myelofibrosis phenotype. Indeed, treatment with a c-Jun N-terminal kinase (JNK) inhibitor prevented
the development of myelofibrosis induced by MPLW515L. Together, these data show that JNK-dependent TGF-β signaling in
mesenchymal stromal cells is responsible for the development of myelofibrosis but not hematopoietic niche disruption in
MPNs, suggesting that the signals that regulate niche gene expression in bone marrow mesenchymal stromal cells are distinct
from those that induce a fibrogenic program.

Introduction

The bone marrow provides a specialized microenvironment that
supports hematopoiesis. Hematopoietic niches in the bone marrow
are dependent, in part, on the constitutive production of certain
cytokines and chemokines by a heterogeneous population of stromal cells. For example, expression of Kit ligand (Kitlg) and CXCL12
by perivascular mesenchymal stromal cells (MSCs) plays an essential role in hematopoietic stem cell (HSC) maintenance (1–3). There
are emerging data suggesting that malignant hematopoietic cells
induce alterations in the bone marrow microenvironment that contribute to hematopoietic phenotypes (4). A better understanding of
the interactions of malignant hematopoietic cells with bone marrow MSCs may identify novel targets for therapeutic intervention.
Myeloproliferative neoplasms (MPNs) are chronic myeloid
malignancies characterized by overproduction of myeloid lineage cells (5). Activating mutations in genes impacting the JAK/
STAT signaling pathway are the major causes of these cancers,
including mutations in JAK2, CALR, and MPL (6). Alterations in
the bone marrow microenvironment are a prominent feature of
MPNs. Most striking is the development of myelofibrosis, which is
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characterized by extensive collagen deposition in the bone marrow
and is associated with a poor prognosis (7, 8). Recent data show that
RNA expression of key niche factors, including Kitlg and Cxcl12, is
reduced in bone marrow MSCs from mouse models of MPNs and
from patients with myelofibrosis (9–11). This is relevant, since studies by our group and others have shown that deleting these niche
factors from stromal cells results in a loss of hematopoietic stem/
progenitor cells (HSPCs) in the bone marrow and development of
extramedullary hematopoiesis (1–3). There is also evidence that
expression of CXCR4, the major receptor for CXCL12, is reduced
on HSPCs in patients with MPNs, which would further reduce
CXCL12 signaling (12). On the other hand, Migliaccio et al. reported that CXCL12 protein expression, as measured by immunostaining, is increased in the bone marrow of patients with MPNs and
in the Gata1low mouse model of MPN (13). Thus, the impact of the
MPN on bone marrow stromal niche factor expression (particularly CXCL12) remains unclear. Finally, there is evidence for altered
bone metabolism in MPNs, with osteosclerosis reported in patients
with myelofibrosis (14). Collectively, these alterations in the bone
marrow microenvironment in MPNs are predicted to reduce its
ability to support hematopoiesis. Indeed, extramedullary hematopoiesis and splenomegaly are common in MPNs.
There is evidence implicating inflammatory mediators in the
development of myelofibrosis. In particular, increased production of
TGF-β produced by megakaryocytes and monocytes is found in most
patients with MPNs (15–19). Using a thrombopoietin (TPO) overexpression model of MPN, Chagraoui et al. showed that deletion
1
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of Tgfb1 reduced but did not completely abrogate the development
of myelofibrosis (20). Likewise, treatment with an inhibitor targeting TGFBR1 (ALK5) reduced myelofibrosis in mouse models
of MPNs (21, 22). However, the role of TGF-β in the development
of myelofibrosis remains controversial. In the aforementioned
studies, although reduced, significant myelofibrosis remained
despite inhibiting TGF-β signaling, raising the possibility that
there are other mediators of myelofibrosis. Consistent with this
possibility, Decker et al. showed that platelet-derived growth factor α (PDGFα) signaling in leptin receptor–positive (Lepr+) MSCs
is required for the development of myelofibrosis (9). Moreover,
Schneider et al. reported that CXCL4 signaling in Gli1+ MSCs contributes to myelofibrosis (10, 23). The cell of origin responsible for
myelofibrosis is also controversial. As noted above, prior studies
have implicated Lepr+ or Gli1+ MSCs as the target of inflammatory
signaling leading to myelofibrosis (9, 10, 23). On the other hand,
there are studies suggesting that monocyte-derived fibrocytes (24,
25) or endothelial cells (26) are the cell of origin.
In this study, we tested the hypothesis that TGF-β signaling in
MSCs contributes to the development of myelofibrosis and hematopoietic niche disruption in MPNs. We show that genetic ablation
of TGF-β signaling in MSCs, but not osteolineage cells, abrogates
myelofibrosis. This effect is mediated by noncanonical c-Jun
N-terminal kinase (JNK) signaling, and treatment of mice with a
JNK inhibitor prevents the development of myelofibrosis. However, loss of TGF-β signaling in MSCs does not rescue the impaired
hematopoietic niche function in MPNs, with persistent decreases
in bone marrow cellularity, HSPC number, and Cxcl12 and Kitlg
expression, and development of extramedullary hematopoiesis.

Results

TGF-β signaling in MSCs is required for the efficient induction of
myelofibrosis by MPLW515L or Jak2V617F in mice. Prior single-cell RNA
sequencing studies of murine bone marrow MSCs show that Tgfbr2
is broadly expressed in MSCs, including Lepr+ perivascular stromal
cells and osteolineage cells (27–31). To investigate the contribution
of TGF-β signaling in MSCs to the pathogenesis of MPN, we used
Osx-Cre Tgfbr2fl/fl mice as transplant recipients of hematopoietic
cells carrying MPLW515L or Jak2V617F. The doxycycline-regulated OsxCre transgene has been shown to target osteoblasts, osteocytes,
adipocytes, and perivascular stromal cells (32). Of note, our group
recently showed that basal hematopoiesis is normal in Osx-Cre Tgfbr2fl/fl mice in which expression of Cre recombinase was activated
at birth by removal of doxycycline, suggesting that TGF-β signaling in MSCs is dispensable for maintenance of the hematopoietic
niche under basal conditions (33). To confirm efficient deletion
of Tgfbr2, we generated Osx-Cre Tgfbr2fl/fl Ai9 mice, in which stromal cells targeted by Osx-Cre express TdTomato. Although Tgfbr2 mRNA expression in sorted TdTomato+ bone marrow MSCs
was significantly reduced in Osx-Cre Tgfbr2fl/fl mice, Cre-mediated excision was incomplete, with Tgfbr2 mRNA levels reduced
by approximately 66% compared with control cells (Figure 1A).
Thus, to increase the percentage of Tgfbr2-deleted stromal cells,
we generated Osx-Cre Tgfbr2fl/– Ai9 mice, in which 1 allele of Tgfbr2 is constitutively deleted. Tgfbr2 mRNA in TdTomato+ stromal
cells was reduced to less than 10% of control cells in these mice.
Moreover, single-cell RNA sequencing of sorted lineage– (CD45 –
2

CD3–B220–Gr-1–CD11b–Ter119–), PDGF receptor β+ (PDGFRβ+)
cells from Osx-Cre Ai9 mice confirmed that the majority (>90%)
of CXCL12+Lepr+ stromal cells expressed tdTomato (Supplemental
Figure 1; supplemental material available online with this article;
https://doi.org/10.1172/JCI154092DS1).
We first used the MPLW515L retroviral model of MPN in which
c-Kit+ cells from WT mice transduced with retrovirus expressing MPLW515L and GFP are transplanted into congenic Tgfbr2fl/fl
or Osx-Cre Tgfbr2fl/– mice; we also included Tgfbr2fl/– mice to control for global Tgfbr2 haploinsufficiency (Figure 1B). Of note,
Tgfb1 mRNA expression in total bone marrow was modestly but
significantly elevated in this model (Figure 1C), with an increase
in TGF-β+ megakaryocytes (Supplemental Figure 2). As reported previously, transplantation of MPLW515L HSPCs into Tgfbr2fl/fl
recipients resulted in a fatal MPN characterized by leukocytosis
and modest erythrocytosis and thrombocytosis (Figure 1, D–H).
A similar hematopoietic phenotype was observed in Osx-Cre
Tgfbr2fl/– recipients and animal survival was not altered. These
data suggest that TGF-β signaling in MSCs is not required for
the development of the lethal myeloproliferative hematopoietic
phenotype induced by MPLW515L.
We next investigated the myelofibrosis phenotype induced by
MPLW515L. As reported previously, transplantation of MPLW515L-transduced HSPCs induced a moderate to severe reticulin fibrosis in
the bone marrow of both Tgfbr2fl/fl and Tgfbr2fl/– recipients (Figure
2, A and B). In contrast, reticulin fibrosis was significantly abrogated in Osx-Cre Tgfbr2fl/– recipients. Since we observed that Tgfbr2fl/fl
and Tgfbr2fl/– recipients have similar phenotypes, we subsequently
pooled data from these 2 groups as WT controls. To further characterize the myelofibrosis phenotype, we assessed collagen I and
III deposition in the bone marrow. In WT recipients transplanted
with MPLW515L-transduced HSPCs, a marked increase in perivascular collagen I and III was observed, which was abrogated in OsxCre Tgfbr2fl/– recipients (Figure 2, C and D). Increased α-smooth
muscle actin (Acta2) expression has been reported in myelofibrosis (10). Indeed, in the MPLW515L transplantation model, Acta2 and
Col3a1 (collagen III) mRNAs were modestly increased, whereas
no elevation was observed in Osx-Cre Tgfbr2fl/– recipients (Figure
2E). Interestingly, modest splenic reticulin fibrosis was induced
after transplantation of MPLW515L-transduced HSPCs in both WT
and Osx-Cre Tgfbr2fl/– recipients (Supplemental Figure 3). Of note,
micro-CT analysis showed that osteosclerosis did not develop in
any of the cohorts (Supplemental Figure 4).
Similar results were observed in a Jak2V617F transgenic model of
MPN. Bone marrow from Jak2V617F mice was transplanted into OsxCre Tgfbr2fl/– or control recipients. Increased Tgfb1 mRNA expression and TGF-β+ megakaryocytes were observed (Figure 3A and
Supplemental Figure 2). The hematopoietic phenotype was similar in all mice, including erythrocytosis, leukocytosis, thrombocytosis, and splenomegaly (Figure 3, B–F). As reported previously
(34), the degree of myelofibrosis in Jak2V617F mice was less severe
than that observed in the MPLW515L model, with no consistent reticulin fibrosis seen. However, increased collagen I and III deposition
in the bone marrow was observed in control, but not Osx-Cre Tgfbr2fl/–, recipients (Figure 3, G and H). Altogether, these data show
that TGF-β signaling in MSCs is required for the development of
myelofibrosis induced by both MPLW515L and Jak2V617F.
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Figure 1. TGF-β signaling in Osx-Cre–targeted mesenchymal stromal cells is not required for the development of the myeloproliferative phenotype by
MPLW515L. (A) Tgfbr2 mRNA expression in sorted lineage–tdTomato+ bone marrow MSCs relative to β-actin mRNA. (B) Schematic of experimental design.
(C) Tgfb1 mRNA expression relative to β-actin in total bone marrow. (D) White blood cell (WBC) count, (E) red blood cell (RBC) count, (F) hematocrit (HCT),
and (G) platelet (PLT) count 4–8 weeks after transplantation and (H) Kaplan-Meier estimates of survival. EV, empty vector; Tx, transplant. Data presented
as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 1-way ANOVA (A and D–G) or Student’s t test (C).

Abrogation of TGF-β signaling in MSCs does not rescue the defective hematopoietic niche in MPLW515L mice. Decreased stromal cell
expression of key niche factors, Cxcl12 and Kitlg, has been reported in several mouse models of MPNs (9–11). Consistent with
these reports, we show that Cxcl12 mRNA expression in the bone
marrow of control recipients transplanted with MPLW515L-transduced HSPCs was markedly decreased (Figure 4A). Surprisingly,
a similar decrease in Cxcl12 mRNA expression was observed in
Osx-Cre Tgfbr2fl/– recipients. Likewise, a modest but significant
decrease in Kitlg mRNA expression in both control and Osx-Cre
Tgfbr2fl/– recipients was observed (Figure 4B). Of note, we and
others previously reported that loss of Cxcl12 or Kitlg expression
in bone marrow MSCs is sufficient to disrupt hematopoietic niches, resulting in a decrease in bone marrow cellularity and HSC
number and development of extramedullary hematopoiesis (1–3).
Indeed, similar decreases in bone marrow cellularity and HSC
number were observed in control and Osx-Cre Tgfbr2fl/– recipients
of MPLW515L-transduced HSPCs (Figure 4, C and D). Moreover,
splenomegaly and significant increases in HSCs and erythroid
progenitors in the spleen were observed in both control and OsxCre Tgfbr2fl/– recipients (Figure 4, E–H, and Supplemental Figure

5). Collectively, these data suggest that, despite the absence of
myelofibrosis, loss of TGF-β signaling in MSCs does not rescue the
defective hematopoietic niche induced by MPLW515L.
Deletion of Tgfbr2 in osteolineage cells does not affect MPLW515Linduced myelofibrosis. Osx-Cre targets a broad range of MSCs,
including osteolineage cells, perivascular CXCL12-abundent
reticular (CAR) cells, and adipocytes (32). To further identify the
stromal cell population responsible for myelofibrosis, we used a
Dmp1-Cre transgene that targets osteoblasts and approximately
30% of CAR cells, which we previously showed are enriched for
osteolineage genes (35). Efficient deletion of Tgfbr2 was confirmed
in TdTomato+ stromal cells isolated from Dmp1-Cre Tgfbr2fl/fl Ai9
mice (Supplemental Figure 6A). As expected, similar alterations
in peripheral blood counts, splenomegaly, and bone marrow cellularity were observed in control and Dmp1-Cre Tgfbr2fl/fl recipients of MPLW515L-transduced HSPCs (Supplemental Figure 6, B–F).
Interestingly, a similar degree of myelofibrosis, as measured by
reticulin staining and Col3a1 mRNA expression, was observed in
control and Dmp1-Cre Tgfbr2fl/fl recipients (Supplemental Figure 6,
G–I). These data show that TGF-β signaling in osteolineage cells is
not required for the development of myelofibrosis.

J Clin Invest. 2022;132(11):e154092 https://doi.org/10.1172/JCI154092
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Figure 2. TGF-β signaling in Osx-Cre–targeted mesenchymal
stromal cells is essential for the development of myelofibrosis by MPLW515L. (A) Representative photomicrographs
of femur sections stained for reticulin (original magnification,
×60). (B) Average score of fibrosis grading in the diaphysis
and epiphysis. (C) Representative photomicrographs of femur
sections stained for collagen I (yellow) or collagen III
(red); nuclei were stained blue with DAPI. Scale bar: 20 μm.
(D) Normalized fluorescence intensity for collagen I and
III. (E) mRNA expression levels of collagen 3 (Col3a1) and
α-smooth muscle actin (Acta2) relative to β-actin mRNA
in total bone marrow. EV, empty vector; TR2fl/fl, Tgfbr2fl/
fl
; TR2fl/–, Tgfbr2fl/–; Osx-TR2fl/–, Osx-Cre Tgfbr2fl/–. Mice were
analyzed 4–8 weeks after transplantation. Data presented as
the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P
< 0.0001 by Kruskal-Wallis test (B) or 1-way ANOVA (D and E).

Canonical (SMAD4-dependent) TGF-β signaling in MSCs is not
required for MPLW515L-induced myelofibrosis. TGF-β signaling consists of SMAD-dependent canonical pathways and the SMADindependent noncanonical pathways. To assess the role of canonical
TGF-β signaling in the development of myelofibrosis, we generated
Osx-Cre Smad4fl/fl mice. Cre-mediated recombination was induced
postnatally by removing doxycycline chow at birth. We previously
showed that deletion of Smad4 is very efficient in Osx-Cre–targeted
cells, with essentially undetectable Smad4 mRNA (36). Of note, we
reported that these mice have normal basal hematopoiesis, with no
identifiable alteration in bone marrow MSCs (36). MPLW515L-transduced HSPCs were transplanted into Osx-Cre Smad4fl/fl recipients
and similar degrees of leukocytosis, erythrocytosis, thrombocytosis, splenomegaly, and reduction in bone marrow cellularity were
4

observed in control and MPLW515L-transduced HSPCs (Supplemental Figure 7). Surprisingly, the degree of myelofibrosis was similar in
control and Osx-Cre Smad4fl/fl recipients, as measured by reticulin
staining (Figure 5, A and B), collagen I and III immunofluorescence
(Figure 5, C and D), and Col3a1 mRNA expression (Figure 5E).
These data suggest that canonical (SMAD4-dependent) TGF-β1
signaling is not required for the development of myelofibrosis in the
MPLW515L murine model of MPN.
JNK activation by TGF-β contributes to the development of
MPLW515L-induced myelofibrosis in mice. Noncanonical TGF-β
signaling includes the activation of extracellular signal–regulated kinase (ERK), JNK, p38, PI3 kinase, and NF-κB pathways
(Figure 6A and ref. 37). Treatment of cultured bone marrow
MSCs with TGF-β1 resulted in increased expression of several

J Clin Invest. 2022;132(11):e154092 https://doi.org/10.1172/JCI154092
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Figure 3. TGF-β signaling in Osx-Cre–targeted mesenchymal stromal cells is essential for the development of myelofibrosis by Jak2V617F. (A) Tgfb1 mRNA
expression relative to β-actin mRNA in total bone marrow. (B) White blood cell (WBC) count, (C) red blood cell (RBC) count, (D) hematocrit (HCT), and (E)
platelet (PLT) count and (F) spleen weight 5 months after tamoxifen-induced Jak2V617F expression. (G) Representative photomicrographs of femur sections
stained for collagen I (yellow) or collagen III (red); nuclei were stained blue with DAPI. Scale bar: 20 μm. (H) Normalized fluorescence intensity for collagen
I and III. Osx-TR2fl/–, Osx-Cre Tgfbr2fl/–. Data presented as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by Student’s t test (A) or
1-way ANOVA (B–E and G).

fibrosis-associated genes, including Loxl1 (which encodes lysyl oxidase–like 1), Col1a1, and Acta2 (Figure 6B and Supplemental Figure 8, A–D). It also resulted in Smad2 and c-Jun phosphorylation,
but not ERK1/2 phosphorylation (Supplemental Figure 8E). Consistent with this result, treatment with PD99059, a MEK inhibitor,
resulted in a modest change in the basal expression of these genes,
but it did not block their induction by TGF-β1 (Figure 6, B and C,
and Supplemental Figure 8, A–D). Treatment with SB202190 (a

p38 inhibitor) or pevonedistat (an NF-κB inhibitor) was associated with a significant decrease in basal Col1a1 and Acta2 mRNA
expression, but also did not prevent TGF-β1–induced increases in
the expression of these genes (Figure 6, B and C, and Supplemental Figure 8, A–D). In contrast, treatment with SP600125, a panJNK inhibitor, significantly reduced TGF-β1–induced increases in
Loxl1, Col1a1, and Acta2 mRNA expression (Figure 6, B and C, and
Supplemental Figure 8, A–D).

J Clin Invest. 2022;132(11):e154092 https://doi.org/10.1172/JCI154092
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Figure 4. TGF-β signaling in Osx-Cre–targeted
mesenchymal stromal cells is not required for
suppression of niche factor gene expression
or development of extramedullary hematopoiesis by MPLW515L. (A and B) mRNA expression of Cxcl12 (A) and Kitlg (B) in total bone
marrow relative to β-actin mRNA. (C) Bone
marrow cellularity per pelvis and (D) number
of phenotypic HSCs (lineage–Sca1+c-kit+CD150+CD48–) in the bone marrow. (E) Spleen
weight and (F) HSC number in spleen. (G and
H) Number of erythroid progenitors in bone
marrow (G) and spleen (H). I, proerythroblast;
II, basophilic erythroblasts; III, polychromatic
erythroblasts; IV, orthochromatic erythroblasts; EV, empty vector; Osx-TR2fl/–, Osx-Cre
Tgfbr2fl/–. Data presented as the mean ± SEM.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001 by 1-way ANOVA.

JNK1 and JNK2, but not JNK3, are expressed in bone marrow
MSCs (38). To determine whether JNK1 or JNK2 selectively contributes to TGF-β–induced myelofibrosis, we used CRISPR/Cas9
gene editing to delete Mapk8 (JNK1) or Mapk9 (JNK2) in MSCs.
Both JNK1 and JNK2 were efficiently deleted (Figure 6D). Deletion
of JNK1 completely abrogated TGF-β–induced Loxl1 expression
and significantly reduced TGF-β–induced Col1a1 and Acta2 expression (Figure 6, E and F). However, deletion of JNK2 did not affect
TGF-β–induced expression of fibrosis-related genes. Collectively,
these data suggest that TGF-β1–induced activation of JNK1 is the
major signal mediating myelofibrosis.
Finally, to assess the impact of JNK activation on the development of myelofibrosis, we treated WT mice transplanted with
MPLW515L-transduced HSPCs with the pan-JNK inhibitor CC-930
(tanzisertib) twice daily for 4 weeks beginning 2 weeks after transplantation. Of note, this regimen was effective in blocking JNK
signaling in lineage– bone marrow MSCs (Supplemental Figure
9). Treatment with CC-930 had no significant effect on MPLW515Linduced leukocytosis, erythrocytosis, thrombocytosis, or splenomegaly (Figure 7, A–D). However, treatment with CC-930 resulted in the
nearly complete abrogation of myelofibrosis, as assessed by reticulin
fibrosis, collagen I deposition, and Col3a1 mRNA expression (Figure
7, E–I). These data show that treatment with the pan-JNK inhibitor
CC-930 prevents induction of myelofibrosis by MPLW515L in mice.
6

Discussion

In this study, we provide strong evidence that TGF-β signaling
in Osx-Cre–targeted MSCs plays an essential role in the develop
of myelofibrosis. These results are consistent with prior studies
showing that genetic or pharmacologic inhibition of TGF-β signaling reduces reticulin fibrosis in TPO overexpression (20) or
GATA1low (21) models of MPNs. In addition, Yue et al. showed that
inhibition of TGF-β using galunisertib, an ALK5 (TGFBR1) inhibitor, reduces, but does not abrogate, myelofibrosis in the clinically
relevant MPLW515L model of MPN. Of note, TGF-β signals through
heterodimers of TGFBR2 with either TGFBR1 (ALK5) or ACVRL1
(ALK1), both of which are expressed at similar levels in bone marrow MSCs (28). Thus, the residual myelofibrosis in galunisertib-treated mice may be due to ALK1-dependent TGF-β signaling.
Consistent with this conclusion, we show that genetic abrogation
of all TGF-β signaling (by deleting Tgfbr2) in MSCs completely prevented the development of myelofibrosis in the majority of mice in
both MPLW515L and Jak2V617F models of MPNs. Although requiring
experimental validation, we suspect that the low-grade myelofibrosis observed in a minority of Osx-Cre Tgfbr2fl/– recipients is due
to inefficient Cre-mediated excision of Tgfbr2.
Prior studies have implicated other inflammatory mediators
in the pathogenesis of myelofibrosis. Decker et al. showed that
reduction of PDGF signaling in MSCs by deletion of Pdgfra or by

J Clin Invest. 2022;132(11):e154092 https://doi.org/10.1172/JCI154092
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Figure 5. Canonical (SMAD4-dependent) TGF-β signaling in mesenchymal stromal cells is not required for the induction of myelofibrosis by MPLW515L.
(A) Representative photomicrographs of femur sections stained for reticulin (original magnification, ×60). (B) Average score of fibrosis grading in the
diaphysis and epiphysis. (C) Representative photomicrographs of femur sections stained for collagen I (yellow) or collagen III (red); nuclei were stained blue
with DAPI. Scale bar: 20 μm. (D) Normalized fluorescence intensity for collagen I and III. (E) Col3a1 mRNA expression relative to β-actin mRNA in total bone
marrow. EV, empty vector; Osx-Smad4fl/fl, Osx-Cre Smad4fl/fl. Mice were analyzed 4 weeks after transplantation. Data presented as the mean ± SEM. *P <
0.05; ***P < 0.001; ****P < 0.0001 by Kruskal-Wallis test (B) or 1-way ANOVA (D and E).

treatment with imatinib reduced myelofibrosis in the TPO overexpression model of MPN (9). However, treatment with PDGF
did not induce fibrogenic gene expression in cultured bone marrow MSCs (Supplemental Figure 10). Whether PDGF signaling in
MSCs provides a permissive signal required for TGF-β–induced
fibrogenic gene expression will require further study. Schenider et
al. reported that increased hematopoietic cell expression of Cxcl4
contributes to the development of myelofibrosis in the TPO overexpression MPN model (10, 23). However, the known receptors
for CXCL4, CXCR3, and CCR1 are not expressed on bone marrow
MSCs (28), suggesting that CXCL4 acts in an indirect fashion to
induce myelofibrosis. Consistent with this conclusion, Schneider
et al. showed that TPO-induced expression of TGF-β in Cxcl4 –/–
megakaryocytes was attenuated (23). Thus, CXCL4 may act
upstream of TGF-β to contribute to myelofibrosis development.
Our data suggest that perivascular MSCs, but not osteoblast-lineage cells, are the key drivers of myelofibrosis. Specifically, we show that abrogation of TGF-β signaling in Osx-Cre–
targeted, but not Dmp1-Cre–targeted stromal cells, prevents the
development of myelofibrosis. These results are consistent with

recent studies suggesting that Lepr+ or Gli1+ MSCs in the bone
marrow are the key drivers of myelofibrosis (9, 10). Of note, constitutively active Lepr-Cre, similarly to postnatal active Osx-Cre,
targets the majority of perivascular MSCs and osteoblasts (39,
40). Likewise, Gli1-Cre targets both perivascular and endosteal MSCs, including osteoblasts (41). Leimkuhler et al. recently
reported results of single-cell RNA sequencing of bone marrow MSCs in a TPO overexpression model of MPN (11). They
showed that adipogenic and osteogenic primitive subsets of
Lepr+ MSCs expanded and upregulated expression of fibrosisrelated genes. Of note, we previously showed that Dmp1-Cre targets an osteogenic subset of CAR (or Lepr+) stromal cells (35).
Together, these data suggest that the adipogenic subset of Lepr+
MSCs is the cell of origin for myelofibrosis.
Our data show that noncanonical JNK-dependent TGF-β signaling is responsible for the induction of myelofibrosis. Deletion
of Smad4 in bone marrow MSCs does not prevent the induction of
myelofibrosis by MPLW515L. In contrast, treatment with a pan-JNK
inhibitor abrogated the development of myelofibrosis by MPLW515L.
This observation is consistent with a prior study showing that

J Clin Invest. 2022;132(11):e154092 https://doi.org/10.1172/JCI154092
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Figure 6. TGF-β contributes to fibrosis-related
gene expression through noncanonical JNK
signaling. (A) TGF-β signaling pathways, with
inhibitors used in this study included. (B) Relative Loxl1 mRNA in WT MSC cultures treated
with TGF-β1 (10 ng/mL) and one of the following inhibitors: the MEK inhibitor PD99059 (20
μM), the p38 inhibitor SB202190 (20 μM), the
NF-κB inhibitor pevonedistat (1 μM), or the JNK
inhibitor SP600125 (20 μM). (C) Fold change
(Δ) in Loxl1 mRNA expression induced by
TGF-β1 in the presence of the indicated inhibitors. (D) Immunoblot showing JNK1 and JNK2
protein expression in control or Mapk8-deleted
(JNK1–/–) or Mapk9-deleted (JNK2–/–) cells.
(E) Relative Loxl1, Col1a1, and Acta2 mRNA
in MSCs treated with TGF-β1 (10 ng/mL). (F)
Fold change in Loxl1, Col1a1, and Acta2 mRNA
expression induced by TGF-β1. Data presented
as the mean ± SEM. *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001 by 2-way ANOVA
(B and E) or 1-way ANOVA (C and F).

expression of c-Jun, a downstream target of JNK, is increased in
all major human fibrotic conditions, including myelofibrosis (42).
Another prior report also found activation of noncanonical TGF-β
signaling, including JUN, in patients with myelofibrosis (43). Of
note, there is evidence of cross-talk between canonical and noncanonical TGF-β signaling. Of particular relevance are data showing
that JNK can phosphorylate and activate SMAD3 (44, 45). Whether the loss of SMAD3 activity contributes to suppression of myelofibrosis after JNK inhibitor treatment will require further study.
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Our data suggest that treatment with JNK inhibitors may have
therapeutic benefit in patients with myelofibrosis, although there
are several important caveats. First, it is not clear whether JNK
inhibitors are able to reverse myelofibrosis after it is established.
Second, our data suggest that reversal of myelofibrosis may not
improve hematopoietic niche function, raising questions about
whether this treatment would significantly impact cytopenias present in many patients with MPN. Finally, a clinical trial of CC-930
(the pan-JNK inhibitor used in our study) in patients with idiopathic
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Figure 7. JNK inhibitor alleviates fibrosis phenotypes in MPLW515L-induced MPN. WT mice transplanted with MPLW515L-transduced HSPCs were treated
with pan-JNK inhibitor CC-930 (tanzisertib) twice daily for 4 weeks beginning 2 weeks after transplantation. (A) White blood cell (WBC) count, (B) red blood
cell (RBC) count, (C) platelet (PLT) count, and (D) spleen weight. (E) Representative photomicrographs of femur sections stained for reticulin (original magnification, ×60). (F) Average score of fibrosis grading in the diaphysis and epiphysis. (G) Representative photomicrographs of femur sections stained for
collagen I (yellow) or collagen III (red); nuclei were stained blue with DAPI. Sacle bar: 20 μm. (H) Normalized fluorescence intensity for collagen I. (I) Col3a1
mRNA expression relative to β-actin mRNA in total bone marrow. EV, empty vector; VE, vehicle-treated control. Data presented as the mean ± SEM. *P <
0.05, **P < 0.01, ****P < 0.0001 by 1-way ANOVA (A–D), Kruskal-Wallis test (F), or Student’s t test (H and I).

pulmonary fibrosis (NCT01203943) was terminated due to an unfavorable benefit/risk profile. Of note, preclinical studies suggesting a
selective role for JNK1 in pulmonary fibrosis have led to an ongoing
clinical trial of CC-90001, a JNK1-selective inhibitor, in patients
with idiopathic pulmonary fibrosis (NCT03142191; ref. 46). Likewise, our in vitro data suggest that JNK1 is the major mediator of
fibrosis-related gene expression in mouse bone marrow MSCs.
Whether treatment with a JNK1-selective inhibitor would prevent
or attenuate myelofibrosis will require further study.
In contrast to myelofibrosis, our data show that TGF-β signaling
in MSCs is not required for the disruption of hematopoietic niches
in MPNs. Specifically, the loss of TGF-β signaling in MSCs did not
prevent the suppression of key niche factors, Cxcl12 and Kitlg, nor
did it prevent the development of extramedullary hematopoiesis

or loss of bone marrow HSCs. Prior studies have established the
importance of Cxcl12 and Kitlg expression in MSCs in the maintenance of a functioning hematopoietic niche. Indeed, deletion
of these genes in Osx-Cre–targeted (or Lepr-Cre–targeted) stromal
cells results in HSPC mobilization and development of extramedullary hematopoiesis (1–3). Based on these observations, we propose that suppression of MSC Cxcl12 and/or Kitlg expression plays
a key role in the disruption of the hematopoietic niche and development of extramedullary hematopoiesis, although we acknowledge that additional data from patients with MPNs is needed to
confirm. These data also show for the first time to our knowledge
that the signals that induce a fibrogenic program in bone marrow
MSCs are distinct from those that suppress Cxcl12 and Kitlg expression. Our data show that the fibrogenic program is dependent
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on TGF-β signaling, while the signals that regulate niche factor
expression remain unknown.
In summary, in this study, we show that noncanonical JNKdependent TGF-β signaling in perivascular MSCs is responsible
for the development of myelofibrosis but not hematopoietic niche
disruption. JNK is a druggable target that may have therapeutic
benefit in the treatment and/or prevention of myelofibrosis in
patients with MPNs.

Methods

Mice. Tgfbr2fl/fl (B6;129-Tgfbr2tm1Karl/J; ref. 47), Osx-Cre (B6.Cg-Tg Sp7-tTA,tetO-EGFP/cre
1Amc/J; ref. 48), Ai9 [B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J;
ref. 49], UBC-CreERT2 (B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J; ref. 50), Jak2V617F
[B6N.129S6(SJL)-Jak2tm1.2Ble/AmlyJ; ref. 34], and Dmp1-Cre [B6N.
FVB-Tg(Dmp1-cre)1Jqfe/BwdJ; ref. 51] mice were obtained from The
Jackson Laboratory. Tgfbr2fl/– mice were generated by breeding Tgfbr2fl/fl with E2A-Cre [B6.FVB-Tg(EIIa-cre)C5379Lmgd/J; ref. 52] mice.
Smad4fl/fl mice were a gift from Fanxin Long, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. All mice
were back-crossed onto the C57BL/6 background and were maintained
under standard pathogen-free conditions. All mice used in this study
were 6 to 12 weeks old. Both male and female mice were used equally in
these studies. To induce recombination postnatally, Osx-Cre Tgfbrfl/– or
Osx-Cre Smad4fl/fl breeders were maintained on 200 ppm doxycycline
chow, which was removed after pups were born.
MPLW515L MPN model. c-Kit+ HSPCs from WT mice were enriched
using murine CD117 (c-Kit) microbeads and the autoMACS Pro Separator system, per the manufacturer’s instructions (Miltenyi Biotec) and
cultured overnight at 37°C with 5% CO2 in stem cell media (MEM-α
with 10% FBS, 100 U penicillin and streptomycin, 10 ng/mL murine
TPO [mTPO], 10 ng/mL mIL-3, 10 ng/mL mFLT3L, and 100 ng/
mL mSCF). To generate retrovirus, the retroviral packaging vector
pCL-Eco was cotransfected with either MSCV-MPLW515L-IRES-GFP or
MSCV-IRES-GFP (empty vector) into 293T cells using calcium phosphate precipitation. Freshly generated retrovirus was added to HSPC
cultures containing polybrene (6 mg/mL). Cells were spin-infected at
1200g at 30°C for 90 minutes and then cultured overnight. Five hundred thousand transduced c-Kit+ cells were injected retro-orbitally
into recipients, which had been irradiated with two 600-cGy doses,
16 hours apart. Recipient mice were placed on prophylactic antibiotics
(trimethoprim-sulfamethoxazole) for 2 weeks following transplantation. Mice were sacrificed for analysis when at least one of the mice in
the same transplanted cohort became moribund, which was around 4
to 8 weeks after transplantation. Of note, at time of terminal analysis,
more than 95% of hematopoietic cells were GFP+.
Jak2V617F MPN model. Donor bone marrow cells were collected
from 6- to 8-week-old UBC-CreERT2 Jak2V617F or UBC-CreERT2 mice, and
2 million bone marrow cells were injected retro-orbitally into lethally
irradiated recipients. Six weeks after transplantation, mice were treated with 3 mg tamoxifen in corn oil daily for 5 days via oral gavage to
induce Cre recombinase activity. Mice were sacrificed for analysis 5
months after tamoxifen induction.
Immunostaining of femur sections. Mouse femurs were fixed in 10%
formalin for 24 to 48 hours at 4°C. Bones were then decalcified in 14%
EDTA, pH 7.4, for 10 to 14 days at 4°C. Following incubation in 30%
sucrose for 24 hours at 4°C to dehydrate, bones were embedded in
optimal cutting temperature compound (OTC, Sakura Finetek). These
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tissue blocks were cut into 12-μm sections using a CryoJane system
(Leica Biosystems). For immunostaining, the slides were blocked with
5% donkey serum in TBST for 1 hour at room temperature. Slides were
then incubated with primary antibody overnight at 4°C, followed by
incubation with secondary antibody for 1 hour at room temperature.
The following antibodies were used: rabbit anti–collagen I (Abcam,
ab34710), rabbit anti–collagen III (Abcam, ab7778), goat anti–TGF-β1
(LAP) (R&D Systems, AB-246-NA), PE–anti-CD41 (BD Biosciences,
MWReg30), and Alexa Fluor 647–conjugated donkey anti–rabbit IgG
(H+L) (Thermo Fisher Scientific). Finally, slides were mounted with
ProLong Gold antifade reagent with DAPI (Life Technologies). Images were acquired with an LSM 700 microscope (Carl Zeiss). Fluorescence intensity was quantified using ImageJ (NIH).
Femur and spleen histology. Mouse femurs and spleens were fixed in
10% formalin for 24 hours at 4°C. Femurs were then decalcified in 14%
EDTA, pH 7.4, for 10–14 days at 4°C. Femurs and spleens were dehydrated via incubation in 30%, 50%, and 70% ethanol for 15 minutes
each. Processed bones and spleens were further embedded in paraffin
and sectioned into 5-μm sections and stained for reticulin fibers by the
Musculoskeletal Research Histology Core at Washington University.
Histologic analysis of femur and spleen tissue. The degree of fibrosis was graded in blinded fashion by 2 independent hematopathologists using adjusted WHO criteria (53). Scores were assigned based
on the degree of fibrosis as well as the percentage of the femur that
was fibrotic: 0, no fibrosis; 1, mild and patchy fibrosis; 2, moderate and
patchy fibrosis; and 3, moderate to severe uniform fibrosis.
Quantitative real-time PCR. To collect total bone marrow RNA,
tibias from mice were either crushed (MPLW515L mice) with a mortar
and pestle in 1 mL of TRIzol (Invitrogen) or flushed (Jak2V617F mice)
with 1 mL of TRIzol. RNA was extracted following the manufacturer’s instructions. cDNA was prepared using iScript reverse transcription supermix (Bio-Rad). Quantitative real-time PCR (qRT-PCR)
was performed using the TaqMan Universal RT Master Mix (Applied
Biosystems). Data were collected on a StepOnePlus Real-Time PCR
System (Applied Biosystems). TaqMan probe primers were all from
Thermo Fisher Scientific: Actb VIC-MGB (Mm04394036_g1), Tgfb1
FAM-MGB (Mm01178820_m1), Tgfbr2 FAM-MGB (Mm03024091_
m1), Col1a1 FAM-MGB (Mm00801666_g1), Col3a1 FAM-MGB
(Mm01254476_m1), Acta2 FAM-MGB (Mm01546133_m1), and Loxl1
FAM-MGB (Mm01145738).
Flow cytometry. Bone marrow and spleen were processed for flow
cytometry as previously described (54). Cells were analyzed on a Gallios flow cytometer (Beckman Coulter). Data analysis was done using
FlowJo version 10.7.1 software (Tree Star). The following antibodies
were used for staining murine cells: anti–Gr-1 (clone RB6-8C5), antiTer119 (clone TER-119), anti-CD117 (clone 2B8), anti-CD48 (clone
HM48-1), and anti-CD140b (PDGFRβ, clone APB5) from eBioscience;
anti-CD45 (clone HI30), anti-CD11b (clone M1/70), anti-B220 (clone
RA3-6B2), anti-CD3e (clone 145-2C11), anti-CD115 (clone AFS98),
anti–Sca-1 (clone D7), anti-CD150 (clone TC15-12F12.2), and antiCD71 (clone RI7217) from BioLegend.
Micro-CT analysis. Mouse femurs were fixed in 10% formalin for
24 hours at 4°C and then dehydrated in 70% ethanol. Processed tissues
were scanned at 10-μm voxel resolution using a Scanco μCT 40 by the
Musculoskeletal Research Histology Core at Washington University.
Bone marrow MSC culture. Total bone marrow cells from 3- to
4-week-old WT or Osx-Cre Smad4fl/fl mice were collected and cultured
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in MSC media (DMEM, 20% FBS, 100 U penicillin and streptomycin)
overnight at 37°C with 5% CO2. Nonattached cells were removed the
next day by gently aspirating the media. Cells were washed with PBS
and fresh medium was added every day for another 2 days. Attached
MSCs were expanded for 3 more days until they reached approximately 80% confluence. MSCs strongly attach to cell culture plates, so after
trypsinization, cells were manually scraped to ensure efficient collection. For TGF-β1 and PDGF stimulation experiments, 200,000 MSCs
were plated per well in 6-well plates and 10 ng/mL TGF-β1, PDGF-AA,
PDGF-BB, or vehicle control (1% bovine serum albumin in PBS) was
added every 24 hours for 3 days. For MAP kinase inhibitor treatments,
20 μM MEK inhibitor (PD99059), p38 inhibitor (SB202190), or JNK
inhibitor (SP600125), or 1 μM NF-κB inhibitor (pevonedistat) or vehicle control (DMSO) were added every 24 hours for 3 days. Twenty-four
hours after the last treatment, cells were lysed with TRIzol, and RNA
was extracted for quantification using qRT-PCR analysis.
CRISPR/Cas9 gene editing. Recombinant Cas9 protein (0.25 μL of
62 μM solution; Alt-R Streptococcus pyogenes Cas9 Nuclease V3, IDT),
1 μL of sgRNAs (50 μM), and 1 μL Buffer T (Neon, Invitrogen) were
incubated at room temperature for 15 to 30 minutes. Cultured MSCs
(100,000 cells) were washed with PBS, resuspended in Buffer T at
13,000 cells/μL, and then added to the Cas9/sgRNA mix. Cells were
nucleofected with 1 pulse at 1500 V for 20 ms using the Neon transfection system (Invitrogen). Cells were allowed to expand in culture
for 72 hours after nucleofection before stimulating with TGF-β1. For
each gene, 3 different sgRNAs targeting the same exon were pooled
to enhance editing efficiency. Sequences of the sgRNAs targeting
exon 3 of Mapk8 (JNK1) were 5′-CATAAGAACTAGTTCTCGGT-3′,
5′-GGGTCTGATTCTGAAATGGC-3′, and 5′-TCGGTAGGCGCGCTTAGCAT-3′. Sequences of the sgRNAs targeting exon 3 of Mapk9 (JNK2)
were 5′-TAAGAGGACGAGTTCACGGT-3′, 5′-TACAGTTCTTGGGATAAATG-3′, and 5′-AGGCTCTCTTTGCGTGCGTT-3′.
Immunoblotting. MSCs were lysed with RIPA buffer (MilliporeSigma) per the manufacturer’s instructions, and proteins were denatured
in SDS sample buffer with 9% β-mercaptoethanol at 100°C for 5 minutes. The following antibodies were used (all purchased from Cell Signaling Technology): anti-SMAD2 (catalog 5339), anti–phospho-SMAD2
(catalog 3104), anti–c-JUN (catalog 9165), anti–phospho-c-JUN (catalog 3270), anti-ERK1/2 (catalog 4695), anti–phospho-ERK1/2 (catalog 4370), anti-JNK1 (catalog 3708), anti-JNK2 (catalog 4672), and
anti-vinculin (catalog 13901).
JNK inhibitor treatment in mice. MPLW515L retrovirus–transduced
HSPCs were transplanted into lethally irradiated WT recipients. Two
weeks after transplantation, mice were treated with vehicle control
(0.5% carboxymethyl cellulose, 0.25% Tween 80) or 50 mg/kg CC-930
(55) (MedChemExpress) twice daily via oral gavage for 4 weeks.
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Single-cell RNA sequencing. Mouse bone marrow from 1 male and
1 female Osx-Cre Ai9 mouse was crushed and dissociated with collagenase II (Worthington). Cells were sorted for lineage– and PDGFRβ+. Sorted cells were captured using 10× Genomics Chromium 3′
gel beads version 3.1. Gene expression libraries were sequenced on a
NovaSeq S4 with the goal of achieving 50,000 reads per cell. A modified reference sequence was created to incorporate the Ai9 reporter
sequence (positions 3897–6222; https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/using/count) into
mm10 for mapping using Cell Ranger v6. Quality filters were applied
to remove cells with mitochondrial transcripts greater than 10% and
UMI counts greater than 50,000. Log normalization, PCA, dimensional reduction, and clustering were performed using the Seurat (v4.1.0)
package in R (v4.1.1); https://www.r-project.org. The single-cell RNA
expression data have been submitted to NCBI’s Gene Expression Omnibus (GEO GSE200693).
Statistics. Unpaired Student’s t test was used to evaluate the significance of differences between 2 groups. One-way ANOVA was used to
evaluate the significance of differences between multiple groups. The
Kruskal-Wallis test was used to evaluate the significance of differences of the categorical fibrosis grades. All data are presented as mean ±
SEM. A P value of less than 0.05 was considered significant.
Study approval. All animal studies were approved by the Institutional Animal Care and Use Committee at Washington University.
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